[Form 4] Precigen, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider purchases reported by Precigen, Inc. director Nancy H. Agee. The Form 4 shows purchases of 15,360 shares at $3.20 on 08/19/2025 and 10,645 shares at $4.6492 on 08/28/2025, increasing her beneficial holdings from 192,196 to 202,841 shares following the latter transaction. The filing was signed on 08/29/2025 and was submitted by an attorney-in-fact.

Positive

• Director Nancy H. Agee made insider purchases totaling 26,005 shares, increasing direct beneficial ownership to 202,841 shares.
• Transactions were disclosed on a timely Form 4 and signed by an authorized attorney-in-fact, indicating compliance with reporting rules.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director purchases 26,005 PGEN shares across two trades, modestly increasing insider ownership.

The transactions total 26,005 shares acquired at weighted prices between $3.20 and $4.6492. Insider buying by a director can signal confidence but the absolute size relative to total outstanding shares is not provided in the filing, so market impact is likely limited. All details reported are non-derivative common stock purchases, and beneficial ownership increased to 202,841 shares as of the last reported trade.

Corporate Governance Expert

TL;DR: Transactions are routine Section 16 disclosures showing a director acquiring common stock via direct ownership.

The Form 4 indicates direct acquisitions by a director with clear transaction codes and prices. The filing is properly signed by an attorney-in-fact. There are no derivative transactions, no dispositions, and no amendments noted. From a governance perspective, the filing documents compliance with insider reporting requirements but provides no further governance actions or plan details.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AGEE NANCY H

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		P		15,360	A	$3.2	192,196	D
Common Stock	08/28/2025		P		10,645	A	$4.6492	202,841	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nancy H. Agee, by Donald P. Lehr, as attorney-in-fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did PGEN director Nancy H. Agee report on Form 4?

The Form 4 reports purchases of 15,360 shares at $3.20 on 08/19/2025 and 10,645 shares at $4.6492 on 08/28/2025.

How many PGEN shares does Nancy H. Agee beneficially own after these transactions?

After the reported purchases, her beneficial ownership is reported as 202,841 shares.

Were any derivative securities (options, warrants) reported in this Form 4 for PGEN?

No. Table II for derivative securities contains no entries; only non-derivative common stock purchases are reported.

When were the Form 4 transactions executed and when was the form signed?

The transactions occurred on 08/19/2025 and 08/28/2025, and the Form 4 was signed on 08/29/2025.

Who filed and signed the Form 4 for Nancy H. Agee?

The Form 4 was signed by /s/ Nancy H. Agee, by Donald P. Lehr, as attorney-in-fact on 08/29/2025.